Ligand (LGND) Breakout! Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Ligand (LGND) Breakout!

LGND 206.36

+1.4%

Nov 26 3:59 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Lyn Benson who wrote (28506)	3/11/1999 9:33:00 AM
From: Henry Niman	Read Replies (1) of 32384

C225 is a monoclonal that targets EGF receptor. SRGN's ONTAK targets IL-2 Receptors, but they have an EGF version also. Thus they can deliver a toxin to tumors over expressing EGF receptor, the same target as C225, and related to the EGF-2 target of GNE's Herceptin (approved for breast cancer).

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next